Results 121 to 130 of about 7,431 (174)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route. [PDF]

Vaccines (Basel)
Mazzotta V, Piselli P, Cozzi Lepri A, Matusali G, Cimini E, Esvan R, Colavita F, Gagliardini R, Notari S, Oliva A, Meschi S, Casetti R, Micheli G, Bordi L, Giacinta A, Grassi G, Gebremeskel Tekle S, Cimaglia C, Paulicelli J, Caioli A, Gallì P, Del Duca G, Lichtner M, Sarmati L, Tamburrini E, Mastroianni C, Latini A, Faccendini P, Fontana C, Nicastri E, Siddu A, Barca A, Vaia F, Girardi E, Maggi F, Antinori A, MPOX Vaccine Lazio Study Group.   +36 more
europepmc   +1 more source

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS). [PDF]

Vaccines (Basel), 2021
Butler C, Ellis C, Folegatti PM, Swayze H, Allen J, Bussey L, Bellamy D, Lawrie A, Eagling-Vose E, Yu LM, Shanyinde M, Mair C, Flaxman A, Ewer K, Gilbert S, Evans TG, On Behalf Of The Invictus Investigators.   +16 more
europepmc   +1 more source

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. [PDF]

Vaccine, 2021
Volkmann A, Williamson AL, Weidenthaler H, Meyer TPH, Robertson JS, Excler JL, Condit RC, Evans E, Smith ER, Kim D, Chen RT, Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG.   +11 more
europepmc   +1 more source

Prospective Surveillance for Cardiac Adverse Events in Healthy Adults Receiving Modified Vaccinia Ankara Vaccines: A Systematic Review

, 2013
Marnie Elizaga, Sandhya Vasan, Mary Marovich, Alicia Sato, Dale N. Lawrence, Bernard Chaitman, Sharon E. Frey, Michael C. Keefer, MVA Cardiac Safety Working Group   +8 more
openalex   +2 more sources

A Novel Monoclonal Antibody Against a Modified Vaccinia Ankara (MVA) Envelope Protein as a Tool for MVA Virus Titration by Flow Cytometry. [PDF]

Viruses
Cua S, Tello BA, Farelo MA, Rodriguez E, Escalante GM, Mutsvunguma LZ, Ogembo JG, Reidel IG.   +7 more
europepmc   +1 more source

Quantitative temporal analysis of modified vaccinia Ankara, the monkeypox and smallpox vaccine

, 2022
Albarnaz JD, Oliveira M, Kite J, Paulo J, Antrobus R, Gygi S, Huttlin E, Smith G, Weekes M.   +8 more
europepmc   +1 more source

Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge. [PDF]

NPJ Vaccines, 2021
Pan Y, Liu L, Tian T, Zhao J, Park CO, Lofftus SY, Stingley CA, Yan Y, Mei S, Liu X, Kupper TS.   +10 more
europepmc   +1 more source

Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants

, 2013
Sharon Melamed, Linda S. Wyatt, Robin J. Kastenmayer, Bernard Moss   +3 more
openalex   +1 more source

Evaluation of modified vaccinia virus Ankara expressing VP2 protein of infectious bursal disease virus as an immunogen in chickens [PDF]

, 2012
Flavia Zanetti, María Paula Del Médico Zajac, Oscar Taboga, Gabriela Calamante   +3 more
openalex   +1 more source

A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. [PDF]

Immunity, 2021
Routhu NK, Cheedarla N, Gangadhara S, Bollimpelli VS, Boddapati AK, Shiferaw A, Rahman SA, Sahoo A, Edara VV, Lai L, Floyd K, Wang S, Fischinger S, Atyeo C, Shin SA, Gumber S, Kirejczyk S, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Upadhyay AA, Pellegrini K, Montefiori D, Shi PY, Menachery VD, Alter G, Vanderford TH, Bosinger SE, Suthar MS, Amara RR.   +31 more
europepmc   +1 more source